Evidence map›Paper›PMID 42780087›Full record

ArticleFrontiers in systems biology2026

Covariate-adjusted AP-1 motif architecture and footprinting track olaparib-adaptive chromatin remodelling.

Subhajit Dutta

Abstract read
In one paragraph

Article in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Subhajit DuttaDepartment of Biochemistry and Molecular Cell Biology (IBMZ), Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription-factor involvement in drug-adaptive chromatin remodelling is often inferred from motif enrichment in differential ATAC-seq peaks, but such analyses can be distorted by sequence composition, peak length, baseline accessibility and redundant motif models. We reanalysed 105,048 consensus ATAC-seq peaks from an olaparib-adapted Kuramochi ovarian-cancer continuum using HOMER-calibrated AP-1/bZIP models with coordinate-level de-duplication. At T320, 27,154 peaks gained and 30,050 lost accessibility. AP-1 motif-occurrence density remained higher in gained chromatin under complementary adjustments: an all-peak spline-adjusted Poisson model gave a rate ratio of 1.90 (95% CI 1.80-2.01), overlap weighting gave 1.95 (1.82-2.11), and 14,046 covariate-matched pairs gave 1.97 (1.90-2.05). Following 35,325 fixed motif-positive/motif-negative peak pairs across the adapted series showed a positive accessibility trend of 0.0363 contrast units per dose doubling (95% CI 0.0195-0.0531). Raw paired-end ATAC-seq footprinting provided an orthogonal signal: AP-1 motif intervals scored above same-length motif-free controls selected within the same accessible peaks in every sample, and the AP-1-specific footprint score increased by 0.00509 per dose doubling after replicate adjustment (HC3 95% CI 0.00081-0.00937; exact stratified permutation P = 0.00211). In a matched-background genome-wide scan, related AP-1/bZIP models occupied the nine highest ranks. Within gained chromatin, motif-positive peaks showed greater adjusted overlap with pooled public AP-1 summits (OR 3.82, 95% CI 3.52-4.15); after collapsing related files by study, 71 study clusters gave a random-effects OR of 2.68 (2.51-2.87), with substantial heterogeneity and a prediction interval of 1.58-4.54. Multi-model single-cell and independent bulk-RNA analyses indicated context-dependent downstream AP-1 output, whereas the two valid comparable drug-free CRISPR contrasts were not FDR-significant. Exploratory nearest-TSS mapping of AP-1-rich gained peaks identified 899 protein-coding genes; recurring GO, Reactome and KEGG themes and STRING associations were used only to provide qualitative, hypothesis-generating functional context. Together, the data support a robust association between AP-1-compatible chromatin architecture and olaparib adaptation, while not establishing AP-1 occupancy, necessity or sufficiency in the studied cells.

Indexed as

AP-1ATAC-seqchromatin accessibilitycovariate adjustmentdigital genomic footprintingmotif enrichmentolaparib adaptationovarian cancer

Identifiers

PMID42780087
PMCPMC13597331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.